Nicholas Mitsiades, M.D., Ph.D.
Professor of Medicine and Chief Translational Officer
Associate Director for Translational Research, UC Davis Comprehensive Cancer Center
To see if Nicholas Mitsiades is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Locations and Contact
UC Davis Comprehensive Cancer Center
UC Davis Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817
Phone: 916-734-5959
Additional Numbers
Clinic Fax
Clinic Referral Phone
Physician Referrals
Philosophy of Care
Dr. Mitsiades is committed to outstanding, innovative, compassionate and equitable care for all patients.
Clinical Interests
Dr. Mitsiades is a Medical Oncologist specialized in the treatment of advanced prostate cancer. He has a long-standing track record in advancing innovative technologies and therapies from the research lab to the clinic in order to improve patient outcomes.
Research/Academic Interests
Dr. Mitsiades has a long-standing track record of innovative research in the lab and in the clinic, with the goal to advance the transfer of novel technologies and therapies from lab to the clinic in order to improve patient outcomes.
Division
Hematology and Oncology
Center/Program Affiliation
Medical School
M.D., University of Athens School of Medicine, Athens, Greece 1995
Other School
Ph.D., Oncology/Endocrinology, University of Athens School of Medicine, Athens, Greece 2001
Internship
Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA 2003-2004
Residency
Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA 2004-2005
Fellowship
Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA 2006-2007
Fellowship
Medical Oncology and Endocrinology, Memorial Sloan-Kettering Cancer Center, New York NY 2007-2010
Elected Member of the American Society for Clinical Investigation, 2019
Sidney Kimmel Foundation Translational Cancer Research Scholar, 2015
Complete List of Published Work in MyBibliography:
http://www.ncbi.nlm.nih.gov/sites/myncbi/nicholas.mitsiades.1/bibliography/40852061/public/?sort=date&direction=descending (includes 155 PubMed-indexed manuscripts, which have received more than 28,000 citations and an H-index of 80).
Kaochar S, Rusin A, Foley C, Rajapakshe K, Robertson M, Skapura D, Mason C, Berman De Ruiz K, Tyryshkin AM, Deng J, Shin JN, Fiskus W, Dong J, Huang S, Navone NM, Davis CM, Ehli EA, Coarfa C, Mitsiades N. Inhibition of GATA2 in prostate cancer by a clinically available small molecule. Endocr Relat Cancer. 2021 Nov 24;29(1):15-31. doi:10.1530/ERC-21-0085. PMID:34636746.
Coarfa C, Fiskus W, Eedunuri VK, Rajapakshe K, Foley C, Chew SA, Shah SS, Geng C, Shou J, Mohamed JS, O'Malley BW, Mitsiades N. Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer. Oncogene. 2016 May 5;35(18):2345-56. doi:10.1038/onc.2015.295. Epub 2015 Sep 14. PubMed PMID:26364608.
He B, Lanz R, Fiskus W, Geng C, Yi P, Hartig SM, Rajapakshe K, Shou J, Wei L, Shah SS, Foley C, Chew SA, Eedunuri VK, Bedoya DJ, Feng Q, Minami T, Mitsiades CS, Frolov A, Weigel NL, Hilsenbeck SG, Rosen DG, Palzkill TG, Ittmann MM, Song Y, Coarfa C, O'Malley BW, Mitsiades N. GATA2 facilitates steroid receptor coactivator (SRC) recruitment to the androgen receptor (AR) complex in prostate cancer cells. Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):18261-6. doi:10.1073/pnas.142141511. PMID:25489091.
Geng C, Rajapakshe K, Shah SS, Shou J, Eedunuri VK, Foley C, Fiskus W, Rajendran M, Chew SA, Zimmermann M, Bond R, He B, Coarfa C, Mitsiades N. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res. 2014 Oct 1;74(19):5631-43. doi:10.1158/0008-5472.CAN-14-0476. Erratum in: Cancer Res. 2019 Sep 1;79(17):4552. PMID:25274033.
Geng C, He B, Xu L, Barbieri CE, Eedunuri VK, Chew SA, Zimmermann M, Bond R, Shou J, Li C, Blattner M, Lonard DM, Demichelis F, Coarfa C, Rubin MA, Zhou P, O'Malley BW, Mitsiades N. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6997-7002. doi:10.1073/pnas.1304502110. Epub 2013 Apr 4. Erratum in: Proc Natl Acad Sci U S A. 2019 Jul 9;116(28):14386-14387. PMID:23559371.
Mitsiades N, Sung CC, Schultz N, Danila DC, He B, Eedunuri VK, Fleisher M, Sander C, Sawyers CL, Scher HI. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res. 2012 Dec 1;72(23):6142-52. doi:10.1158/0008-5472.CAN-12-1335. Epub 2012 Sep 12. PMID:22971343.
Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010 Jul 13;18(1):11-22. doi:10.1016/j.ccr.2010.05.026. Epub 2010 Jun 24. PMID:20579941.
Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003 Mar 15;101(6):2377-80. doi:10.1182/blood-2002-06-1768. Epub 2002 Nov 7. PMID:12424198.
Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9. doi:10.1073/pnas.202445099. Epub 2002 Oct 21. PMID:12391322.